أعرض في EDS

P4-663: INITIATION OF THE PHASE 2/3 GAIN TRIAL OF COR388, A NOVEL BACTERIAL VIRULENCE FACTOR INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD) BASED ON PHASE I A/B SAFETY, PK, BIOMARKER AND EFFICACY DATA

التفاصيل البيبلوغرافية
العنوان:	P4-663: INITIATION OF THE PHASE 2/3 GAIN TRIAL OF COR388, A NOVEL BACTERIAL VIRULENCE FACTOR INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD) BASED ON PHASE I A/B SAFETY, PK, BIOMARKER AND EFFICACY DATA
المؤلفون:	Ira J. Goodman, Mark I. Ryder, Stephen G. Thein, Ursula Haditsch, Mike Detke, Dave Hennings, Leslie J. Holsinger, Shirin Kapur, Steve Dominy, Casey C. Lynch, Florian Ermini, Debasish Raha
المصدر:	Alzheimer's & Dementia. 15:P1585-P1585
بيانات النشر:	Wiley, 2019.
سنة النشر:	2019
مصطلحات موضوعية:	Epidemiology, business.industry, Health Policy, Disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Bacterial virulence, Cancer research, Biomarker (medicine), Medicine, Neurology (clinical), Geriatrics and Gerontology, business
تدمد:	1552-5260
URL الوصول:	https://explore.openaire.eu/search/publication?articleId=doi_________::80466dde04acca93c34519ea527d9783 https://doi.org/10.1016/j.jalz.2019.09.029
حقوق:	OPEN
رقم الأكسشن:	edsair.doi...........80466dde04acca93c34519ea527d9783
قاعدة البيانات:	OpenAIRE

الوصف
تدمد:	15525260